A multicenter cohort of transgender and gender diverse people with multiple sclerosis
The current findings, that a well-educated, well-insured TGD PwMS cohort (primarily AFAB) on high-efficacy disease-modifying therapy (DMT) had overall mild disease, provides reassurance for TGD about their MS disease trajectory and did not detect any concerns regarding exogenous testosterone.
Authors
- Tamara Kaplan (ORCID: https://orcid.org/0000-0002-6262-6960)
- Talia Feldman
- Meagan Harms
- Alexandra Balshi (ORCID: https://orcid.org/0000-0002-3202-6921)
- Riley M. Bove (ORCID: https://orcid.org/0000-0002-2034-8800)
- Jacob A. Sloane (ORCID: https://orcid.org/0000-0003-0028-3031)
- Tanuja Chitnis (ORCID: https://orcid.org/0000-0002-9897-4422)
- Ursela Baber
- Joshua Katz (ORCID: https://orcid.org/0000-0003-0596-7854)
- Jaime Imitola
- John P Dempsey
- Emily Carrizzo
- Paige Greenawalt
Institutions
- Beth Israel Deaconess Medical Center (US)
- University of Massachusetts Chan Medical School (US)
- Multiple Sclerosis Center Of Northeastern New York (US)
- Mass General Brigham (US)
- UConn Health (US)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1177/13524585251383330
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47